QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.057521v1 308/1/91    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kawaguchi, H. Articles by Takakura, Y. Search for Related Content PubMed PubMed Citation Articles by Kawaguchi, H. Articles by Takakura, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DIGOXIN TRITIUM

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Effect of Interferon- on the Pharmacokinetics of Digoxin, a P-glycoprotein Substrate, Intravenously Injected into the Mouse

Department of Biopharmaceutics and Drug Metabolism (H.K., Y.M., Y.T.) and Department of Molecular Microbiology (Y.W.), Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan

P-glycoprotein (P-gp) is an efflux transporter with a wide substrate specificity that plays an important role in the disposition of drugs in the epithelial cells of various tissues, such as the gastrointestinal tract, liver, and kidney. One characteristic feature of this efflux transporter is that its expression and activity are modulated by various factors, including cytokines. Here, we investigated the effect of interferon- (IFN-) on the transport activity of P-gp and its expression in mice, since the cytokine is induced by various stimuli and capable of provoking a variety of cellular responses. Twenty-four hours after a single intraperitoneal injection of IFN- (1 x 10⁵ U), mice were intravenously injected with [³H]digoxin, a P-gp substrate, and its pharmacokinetics was examined. IFN- pretreatment resulted in retardation of plasma elimination of the drug with a concomitant increase of its tissue levels in liver, kidney, and intestine. Furthermore, the excretion of [³H]digoxin into the urine and bile, but not into the intestinal lumen, was significantly reduced: the urinary and biliary excretion clearances in IFN--treated mice were 65 and 55%, respectively, of those clearances in untreated mice. However, the P-gp expression levels were only slightly reduced (20–30% reduction) by IFN- treatment in the liver, kidney, or intestine on Western blot analysis. IFN- also caused a slight down-regulation (20–30% reduction) in the expression of cytochrome P450 3A (CYP3A) on Western blot analysis. Thus, a more pronounced effect may be elicited by IFN- for common substrates of P-gp and CYP3A.

Address correspondence to: Dr. Yoshinobu Takakura, Department of Drug Metabolism and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. E-mail: takakura{at}pharm.kyoto-u.ac.jp

This article has been cited by other articles:

				A. Kimura, Y. Ishida, T. Hayashi, T. Wada, H. Yokoyama, T. Sugaya, N. Mukaida, and T. Kondo Interferon-{gamma} Plays Protective Roles in Sodium Arsenite-Induced Renal Injury by Up-Regulating Intrarenal Multidrug Resistance-Associated Protein 1 Expression Am. J. Pathol., October 1, 2006; 169(4): 1118 - 1128. [Abstract] [Full Text] [PDF]

				S. G. Dixit, B. Zingarelli, D. J. Buckley, A. R. Buckley, and G. M. Pauletti Nitric oxide mediates increased P-glycoprotein activity in interferon-{gamma}-stimulated human intestinal cells Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G533 - G540. [Abstract] [Full Text] [PDF]